期刊文献+

唑来膦酸联合化疗治疗非小细胞肺癌骨转移的疗效观察 被引量:10

Effect of zoledronic acid injection and vinorelbine combined with cisplatin on non-small cell lung cancer with bone metastases
下载PDF
导出
摘要 目的探讨唑来膦酸注射液配合长春瑞滨联合顺铂化疗治疗非小细胞肺癌(NSCLC)骨转移的疗效。方法将48例非小细胞肺癌骨转移患者随机分为唑来膦酸注射液加化疗组(治疗组)及单纯化疗组(对照组)各24例,治疗组接受包括唑来膦酸治疗、化疗、支持治疗的综合治疗,观察骨转移灶改变情况,疼痛改善情况,血清AKP、血清钙以及肌酐的改变情况。对照组接受化疗及支持治疗,且化疗方案同治疗组。两组患者在治疗两个周期后评价疗效,对比两组的疼痛缓解率、血清AKP、血清钙以及肌酐的变化。结果治疗组的疼痛缓解率明显高于对照组,且治疗组血清AKP、血清钙在治疗后明显下降(均P<0.05);血清肌酐在治疗前后无明显改变(P>0.05)。结论唑来膦酸治疗非小细胞肺癌骨转移止疼效果好,安全且不良反应较小,与化疗配合效果更佳。 Objective To explore the effect of zoledronic acid injection and vinorelbine combined with cisplatin on non-small cell lung cancer with bone metastases. Methods 48 patients with non-small cell lung cancer and bone metastasis were ran- domly divided into treatment group treated with zoledronic acid injection and vinorelbine combined with cisplatin (24 cases) and control group treated with of pure chemotherapy group (24 cases). The treatment of treatment group included zoledronic acid injection and vinorelbine combined with cisplatin, support of comprehenslve treatment. The improvement of bone metastases pain to the situation, AKP, serum calcium and serum creatinine were observed. The control group was treated with chemotherapy and support treatment. The curative effect, pain relief rate, the change of AKP, serum calcium and serum creatinine were observed. Results Pain remission rate of treatment group was obviously higher than that of control group. The serum AKP and serum calcium of the treatment group significantly decreased after treatment. Serum creatinine has no obvious change before and after therapy. Conclusion Zotedronic acid injection to treat non-small cell lung cancer (NSCLC) bone metastases is effective and safe.
出处 《西部医学》 2015年第9期1335-1337,共3页 Medical Journal of West China
基金 河南省教育厅自然科学基金(200510471009 2011A360008)
  • 相关文献

参考文献10

二级参考文献43

  • 1张晓春,梁荣祥,张艳丽,李秀菊,张雪艳.肺癌骨转移综合治疗疗效分析[J].中华肿瘤杂志,1996,18(5):327-327. 被引量:11
  • 2Rosen CJ, Kessenich CR. Comparative clinical pharmacology and therapeutic use of bispkosphonates in metabolic bone diseases.Drugs, 1996, 51 (4): 537~551. 被引量:1
  • 3Fitton A, Mc Tavish D. A review of its phannacological properties and therapeutic efficacy in resorptive bone disease. Drug,1991, 42: 289~318. 被引量:1
  • 4Johnson DH. Treatmint strategies for metastatic non small cell lung cancer. Clin Lung Cancer, 1999, 1: 34~41. 被引量:1
  • 5Rosin LS, Gordo D, Tchekmedyian NS. Long-term efficacy and safety of zoledronic acid in the treatmint of skeletal metastases in patients with non small cell lung carcinoma and other solid tumors: a randomized, Phase Ⅲ double-blind, placebo-controlled trial. Cancer, 2004, 100 (12): 2613~2621. 被引量:1
  • 6Major PP, Coleman RE. Zoledronic acid in the treatment of hypercalcemia of malignancy: results of the international clinical development program[J]. Semin Oncol, 2001, 28(2 Suppl 6):17~24. 被引量:1
  • 7Cheer SM. Zoledronic acid[J]. Drugs, 2001, 61(6):799~805. 被引量:1
  • 8BerensonJR. A phase I dose-ranging trial of monthly infusions of zoledronic acid for the treatment of osteolytic bone metastases [J].Clin Cancer Res, 2001, 7(3):478~485. 被引量:1
  • 9Rosen LS. Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase Ⅲ, double-blind, comparative trial[J]. Cancer J, 2001, 7(5):377~387. 被引量:1
  • 10Skerjanec A, BerensonJ, Hsu C, et al. The Pharmacokinetics and Pharmacodynamics of Zoledronic Acid in Cancer Patients with Varying Degrees of Renal Function[J]. J Clin Pharmacol, 2003, 43(2):154~ 162. 被引量:1

共引文献73

同被引文献117

引证文献10

二级引证文献67

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部